Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01945359 · ClinicalTrials.gov registry record
Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design
A clinical trial, sponsored by Rocky Mountain MS Research Group.
- Completed
- Registry status
- 30
- Enrollment target
NCT01945359: Completed study, sponsored by Rocky Mountain MS Research Group.
NCT01945359 is a clinical trial that has completed, run by Rocky Mountain MS Research Group. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01945359 has completed, sponsored by Rocky Mountain MS Research Group.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study will observe participants with relapsing remitting multiple sclerosis who are switching therapies from natalizumab to dimethyl fumarate to determine disease stability.
Primary Outcome
Disease stability as measured by stable Expanded Disability Status Scale (EDSS) and no significant changes on magnetic resonance imaging lesions or relapses.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-06 |
What the finished NCT01945359 record still lists
NCT01945359 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01945359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01945359 about?
NCT01945359 is a clinical study titled "Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design". This study will observe participants with relapsing remitting multiple sclerosis who are switching therapies from natalizumab to dimethyl fumarate to determine disease stability.
What is the current status of trial NCT01945359?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2013-09. Estimated completion is 2015-06.
Who is sponsoring clinical trial NCT01945359?
This trial is sponsored by Rocky Mountain MS Research Group, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia